{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T01:00:49Z","timestamp":1692666049126},"reference-count":19,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,25]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n The objective of the study was to evaluate the long-term outcome of paediatric-onset hyperthyroidism with follow-up into adulthood and to identify any early predictors of a need for definitive therapy (DT).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In a retrospective analysis of patients diagnosed with hyperthyroidism under the age of 18 years and at follow-up, a comparison was made by categorising them into those who underwent definitive therapy (DT group), i.e. thyroidectomy\/radioactive iodine (RAI), those who remained on antithyroid drugs (ATD) (CBZ group) and those who had complete remission (RE group).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Sixty-one (49 females, 12 males) patients with a median age of 15.1 years (range: 3.6\u201318) at diagnosis were studied. The duration of the first course of ATD varied from <1 year (7%), 1\u20132 years (26%), >2 years (46%) and ATD never discontinued (21%). Disease relapsed in 69% of patients with <1 year of ATD vs. 79% with >2 years of ATD. At follow-up, the median duration since diagnosis was 8.75 years (range 2.0\u201320.7 years) and the median age at follow-up was 23.2 years (8\u201336 years). Thirty-three percent (20\/61) had undergone DT (DT group) \u2013 with 16.5% (n=10) on RAI and 16.5% (n=10) on surgery, 36% (22\/61) were on ATD (CBZ group), whilst 32% (19\/61) had undergone full remission (RE group). The comparison did not identify any statistically significant difference for predictor factors at diagnosis including age, T4 and free T4 levels, thyroid peroxidise antibody levels (TPO) and the duration of the first course of carbimazole (CBZ) treatment.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Long-term complete remission of paediatric-onset hyperthyroidism in our study was 31%. There were no predictors identified that could help predict the long-term outcome, especially into adulthood.<\/jats:p>\n <\/jats:sec>","DOI":"10.1515\/jpem-2018-0385","type":"journal-article","created":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T20:00:33Z","timestamp":1548532833000},"page":"151-157","source":"Crossref","is-referenced-by-count":4,"title":["Long-term outcome of hyperthyroidism diagnosed in childhood and adolescence: a single-centre experience"],"prefix":"10.1515","volume":"32","author":[{"given":"Daniel S.","family":"Gill","sequence":"first","affiliation":[{"name":"Paediatric Department , University Hospital of Leicester \u2013 Leicester Royal Infirmary , Leicester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Greening","sequence":"additional","affiliation":[{"name":"Paediatric Department , University Hospital of Leicester \u2013 Leicester Royal Infirmary , Leicester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor A.","family":"Howlett","sequence":"additional","affiliation":[{"name":"Endocrinology Department , Leicester Centre for Genetics, Endocrinology and Metabolism, Leicester Royal Infirmary , Leicester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles J.","family":"Levy","sequence":"additional","affiliation":[{"name":"Endocrinology Department , Leicester Centre for Genetics, Endocrinology and Metabolism, Leicester Royal Infirmary , Leicester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savitha D.","family":"Shenoy","sequence":"additional","affiliation":[{"name":"Paediatric Department , University Hospital of Leicester \u2013 Leicester Royal Infirmary , Leicester , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,1,26]]},"reference":[{"key":"2023040100395063070_j_jpem-2018-0385_ref_001_w2aab2b8c46b1b7b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. Clin Endocrinol (Oxf) 2010;72:358\u201363.","DOI":"10.1111\/j.1365-2265.2009.03717.x"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_002_w2aab2b8c46b1b7b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Birrell G, Cheetham T. Juvenile thyrotoxicosis: can we do better? Arch Dis Child 2004;89:745\u201350.","DOI":"10.1136\/adc.2003.035980"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_003_w2aab2b8c46b1b7b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Bossowski AT, Reddy V, Perry LA, Johnston LB, Banerjee K, et al. Clinical and endocrine features and long-term outcome of Graves\u2019 disease in early childhood. J Endocrinol Invest 2007;30:388\u201392.","DOI":"10.1007\/BF03346315"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_004_w2aab2b8c46b1b7b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Lee HS, Hwang JS. The treatment of Graves\u2019 disease in children and adolescents. Ann Pediatr Endocrinol Metab 2014;19:122\u20136.","DOI":"10.6065\/apem.2014.19.3.122"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_005_w2aab2b8c46b1b7b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Bauer AJ. Approach to the pediatric patient with Graves\u2019 disease: when is definitive therapy warranted? J Clin Endocrinol Metab 2011;96:580\u20138.","DOI":"10.1210\/jc.2010-0898"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_006_w2aab2b8c46b1b7b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves\u2019 disease: a prospective, multicenter study. Pediatrics 2008;121:e481\u20138.","DOI":"10.1542\/peds.2007-1535"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_007_w2aab2b8c46b1b7b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Azizi F, Amouzegar A. Management of thyrotoxicosis in children and adolescents: 35 years\u2019 experience in 304 patients. J Pediatr Endocrinol Metab 2018;31:159\u201365.","DOI":"10.1515\/jpem-2017-0394"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_008_w2aab2b8c46b1b7b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"John M, Sundrarajan R, Gomadam SS. Anti-thyroid drugs in pediatric Graves\u2019 disease. Indian J Endocrinol Metab 2015;19:340\u20136.","DOI":"10.4103\/2230-8210.152766"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_009_w2aab2b8c46b1b7b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism. Cochrane Database Syst Rev 2005;18:CD003420.","DOI":"10.1002\/14651858.CD003420.pub3"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_010_w2aab2b8c46b1b7b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987;64:1241\u20135.","DOI":"10.1210\/jcem-64-6-1241"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_011_w2aab2b8c46b1b7b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 1997;82:1719\u201326.","DOI":"10.1210\/jc.82.6.1719"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_012_w2aab2b8c46b1b7b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves\u2019 disease is radioiodine. J Clin Endocrinol Metab 2007;92:797\u2013800.","DOI":"10.1210\/jc.2006-1239"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_013_w2aab2b8c46b1b7b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Gruneiro-Papendieck L, Chiesa A, Finkielstain G, Heinrich JJ. Pediatric Graves\u2019 disease: outcome and treatment. J Pediatr Endocrinol Metab 2003;16:1249\u201355.","DOI":"10.1515\/JPEM.2003.16.9.1249"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_014_w2aab2b8c46b1b7b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, et al. Antithyroid drug treatment for Graves\u2019 disease in children: a long-term retrospective study at a single institution. Thyroid 2013;24: 200\u20137.","DOI":"10.1089\/thy.2012.0612"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_015_w2aab2b8c46b1b7b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Mussa GC, Corrias A, Silvestro L, Battan E, Mostert M, et al. Factors at onset predictive of lasting remission in pediatric patients with Graves\u2019 disease followed for at least three years. J Pediatr Endocrinol Metab 1999;12:537\u201341.","DOI":"10.1515\/JPEM.1999.12.4.537"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_016_w2aab2b8c46b1b7b1ab2b1c16Aa","unstructured":"LaFranchi S. Clinical manifestation and diagnosis of hyperthyrodiism in children and adoelscents. UpToDate 2018."},{"key":"2023040100395063070_j_jpem-2018-0385_ref_017_w2aab2b8c46b1b7b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Shulman DI, Muhar IV, Jorgensen EV, Diamond FB, Bercu BB, et al. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid 1997;7:755\u201360.","DOI":"10.1089\/thy.1997.7.755"},{"key":"2023040100395063070_j_jpem-2018-0385_ref_018_w2aab2b8c46b1b7b1ab2b1c18Aa","unstructured":"Howlett TA, Kieffer V, Robinson C, Peat IM, Kong M-F, et al. Review of a thyrotoxicosis shared-care scheme: treatment choice and outcomes. International\/European Congress of Endocrinology, Florence, 2012. (Endocrine Abstracts (2012) 29:P1654."},{"key":"2023040100395063070_j_jpem-2018-0385_ref_019_w2aab2b8c46b1b7b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Kaguelidou F, Alberti C, Castanet M, Guitteny M-A, Czernichow P, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008;93:3817\u201326.","DOI":"10.1210\/jc.2008-0842"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpem.2019.32.issue-2\/jpem-2018-0385\/jpem-2018-0385.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2018-0385\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2018-0385\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T16:10:22Z","timestamp":1680365422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2018-0385\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,26]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,1,26]]},"published-print":{"date-parts":[[2019,2,25]]}},"alternative-id":["10.1515\/jpem-2018-0385"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2018-0385","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,26]]}}}